Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15,158
ISIN
US75886F1075
Website
Regeneron Metrics
BasicAdvanced
$52B
12.43
$39.43
0.43
$0.88
0.72%
Price and volume
Market cap
$52B
Beta
0.43
52-week high
$1,206.81
52-week low
$485.00
Average daily volume
1.4M
Dividend rate
$0.88
Financial strength
Current ratio
5.708
Quick ratio
5.017
Long term debt to equity
9.204
Total debt to equity
9.204
Dividend payout ratio (TTM)
2.08%
Interest coverage (TTM)
82.68%
Management effectiveness
Return on assets (TTM)
6.91%
Return on equity (TTM)
15.96%
Valuation
Price to earnings (TTM)
12.435
Price to revenue (TTM)
3.746
Price to book
1.77
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
17.816
Dividend yield (TTM)
0.18%
Forward dividend yield
0.72%
Growth
Revenue change (TTM)
7.52%
Earnings per share change (TTM)
16.49%
3-year revenue growth (CAGR)
-5.15%
3-year earnings per share growth (CAGR)
-17.53%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
Barrons·21 minutes ago
Regeneron's weight-loss drug helps preserve muscle mass in study
Reuters·51 minutes ago
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
GlobeNewsWire·1 hour ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun6
Regeneron
Dividend·Payment
$0.88Per share
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $52B as of June 02, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 12.43 as of June 02, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of June 02, 2025, the dividend rate is $0.88 and the yield is 0.72%. Regeneron has a payout ratio of 2.08% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment is scheduled for June 06, 2025.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.